MONMOUTH JUNCTION, N.J.,
Nov. 5, 2018 /PRNewswire/ -- DiamiR,
a developer of innovative, minimally invasive diagnostic tests for
neurodegenerative and other diseases, announced today two
publications in Aging:
Experimental paper: Age- and sex-related changes in levels of
circulating brain-enriched microRNAs during normal aging
[https://doi.org/10.18632/aging.101613] and
Theory paper: Aging and aging-associated diseases: a
microRNA-based endocrine regulation hypothesis
[https://doi.org/10.18632/aging.101612]
The study reported in the experimental paper was conducted in
collaboration with the New York Blood Center and supported by a
Small Business Innovation Research grant from the National
Institute on Aging. Levels of specific brain-enriched and
inflammation-associated microRNAs were analyzed in plasma samples
from individuals of different ages ranging from 26 to 75 years old.
Dynamic changes in the plasma concentrations of certain microRNAs
occurred at different ages in females and males, with peaks in the
46-55-year-old and 56-65-year-old groups, respectively. The
findings suggest that the changes in microRNA levels could be
reflective of centrally regulated processes, including changes in
hormone levels during menopause.
In the related theory paper published in the same issue, Dr.
Samuil Umansky, Chief Scientific
Officer of DiamiR, proposes the microRNA-based endocrine regulation
hypothesis based on central regulation of cell death occurrences
via hypothalamus-pituitary gland-secreted "microRNA hormones", the
expression and/or secretion of which are regulated by sex
hormones.
"Aging is a major risk factor for many diseases. The development
of reliable biomarkers for monitoring of aging should lead to a
better understanding of aging-associated processes and facilitate
the development of aging-delaying therapies," commented Dr.
Umansky. "The work we reported builds on our earlier studies on
circulating brain-enriched microRNAs as biomarkers of
neurodegenerative diseases. The analysis of brain-enriched microRNA
circulating in plasma can provide information about age-related
changes in the regulation of metabolic processes in the body.
Further, the sex-dependent differences in plasma concentrations of
certain microRNAs support the proposed hypothesis explaining such
known phenomena as inverse comorbidity between cancer and
Alzheimer's (AD) and other neurodegenerative diseases; higher AD
morbidity in women vs. men; higher risk of early AD and reduced
risk of solid tumors in individuals with Down syndrome, and others.
We believe that brain- and other organ-enriched microRNAs
circulating in plasma hold strong promise as biomarkers and
potentially even as therapeutic agents for normal and pathological
aging."
About DiamiR
DiamiR Biosciences is a privately held
molecular diagnostics company focused on developing minimally
invasive tests for mild cognitive impairment, Alzheimer's disease,
and other conditions. The proprietary technology is based on
quantitative analysis of organ-enriched microRNA signatures in
plasma and is being developed for early diagnosis and patient
stratification, as well as disease progression and treatment
monitoring. DiamiR collaborates with leading academic centers,
disease foundations, and pharma companies. For more information,
please visit the company's website
at www.diamirbio.com.
Please Note: This news release contains
forward-looking statements regarding future events. These
statements are predictions and are subject to risks and
uncertainties that could cause the actual events or results to
differ materially.
Contact:
Kira
Sheinerman, PhD
917-678-0990
ksheinerman@diamirbio.com
View original
content:http://www.prnewswire.com/news-releases/diamir-announces-two-publications-on-microrna-biomarkers-and-mechanisms-of-aging-300744073.html
SOURCE DiamiR